JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for it ...

Core Insights - VivoSim Labs, Inc. has appointed Dr. Amar Sethi as Chief Scientific Officer to enhance its scientific strategy and capabilities in drug testing and toxicology [1][5] Company Overview - VivoSim Labs is a pharmaceutical and biotechnology services company focused on testing drugs in three-dimensional human tissue models, specifically for liver and intestine [6] - The company anticipates increased adoption of its human tissue models following FDA's announcement to refine animal testing requirements in favor of non-animal methods [6] Leadership Appointment - Dr. Amar Sethi brings three decades of experience in pharmaceutical drug development, CRO leadership, and diagnostic innovation [2] - His previous roles include leading global clinical programs and developing FDA-qualified biomarker platforms, contributing to significant business growth [4] Strategic Focus - Dr. Sethi will lead initiatives in toxicology, translational models, and bioanalytics, aiming to enhance multi-parametric toxicity prediction using human-relevant systems [3] - The company aims to integrate advanced 3D biology with AI-driven analytics to provide earlier decision-ready insights for sponsors [5] Market Positioning - VivoSim Labs is positioned to be a preferred scientific partner as the industry increasingly adopts 3D NAM systems for drug development [5]

Core Points - Charles River Laboratories announced the resignation of CFO Flavia H. Pease, effective September 29, 2025, and appointed Michael G. Knell as interim CFO while a search for a permanent successor is conducted [1][2] - The company reaffirmed its financial guidance for 2025, including revenue and non-GAAP earnings per share, based on its current outlook for third-quarter performance [3] Management Transition - Flavia H. Pease contributed significantly during her three years at the company, helping to navigate challenging demand environments and optimize cost structures [2] - Michael G. Knell, who has been with the company since 2017, is expected to lead the finance organization effectively during the interim period [2] Financial Guidance - The company maintains its previously provided financial guidance for 2025, indicating confidence in its revenue and earnings projections [3]

Core Insights - VivoSim Labs has appointed Tony Lialin as Chief Commercial Officer to enhance its AI-enabled NAMkind™ liver and intestine toxicology services in a growing market [1][2] - The global market for liver and gastrointestinal in-vitro models and toxicology services generated $641 million in revenue in 2024, with services accounting for 53.1% of this revenue [3] - The U.S. market for liver toxicology models and services is valued at $325 million, representing 50.8% of the global market [3] Market Opportunity - The global in vitro liver model market is experiencing a growth rate of 5.9% CAGR from 2020 to 2024, indicating increasing adoption of 3D human-relevant systems [3] - Regulatory changes, such as the FDA Modernization Act 2.0, are driving the adoption of non-animal methodologies, which supports the use of human-relevant in vitro models for ADME and toxicology [4] Technology and Services - VivoSim Labs utilizes AI to enhance the analysis of multi-parametric toxicity signatures in liver and intestinal organoid assays, improving the reliability of dose-response analyses [5] - The company's NAMkind™ models are designed to provide critical toxicology insights earlier in the drug development process, aiming to streamline pre-IND decision-making [6] Company Overview - VivoSim Labs focuses on testing drugs and drug candidates using 3D human tissue models of the liver and intestine, offering insights through its NAM models [7] - The company anticipates increased adoption of its human tissue models following recent FDA announcements aimed at refining animal testing requirements [7]